Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

GlycoMimetics logo

About GlycoMimetics Stock (NASDAQ:GLYC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$27.47
52-Week Range
N/A
Volume
1.05 million shs
Average Volume
67,672 shs
Market Capitalization
$10.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GLYC Stock News Headlines

Geron Names Harout Semerjian President, CEO
Crescent Biopharma Inc.
Sell this, buy that
What you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strategy: Sell This, Buy That. In his newest presentation, Eric reveals 7 new trade ideas—pairing overhyped, vulnerable stocks with lesser-known opportunities showing real upside. These contrarian picks come from the same approach that helped him beat Wall Street legends 10-to-1 in Portfolios with Purpose.tc pixel
See More Headlines

GLYC Stock Analysis - Frequently Asked Questions

GlycoMimetics, Inc. (NASDAQ:GLYC) issued its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported ($4.00) earnings per share for the quarter, topping analysts' consensus estimates of ($5.00) by $1.00.

Shares of GlycoMimetics reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/14/2025
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLYC
CIK
1253689
Employees
50
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Net Margins
N/A
Pretax Margin
-397,340.00%
Return on Equity
-230.74%
Return on Assets
-177.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.92
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
64,532,000
Free Float
58,901,000
Market Cap
$10.00 million
Optionable
Optionable
Beta
1.62

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:GLYC) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners